Autolus Therapeutics Q3 net loss $82M; FDA approval of AUCATZYL triggers $30M milestone

Autolus Therapeutics plc

2024-Q3 EPS reported -$0.77 revenue$10,091,000

FDA approved AUCATZYL (obe-cel) for adult r/r B-ALL on Nov 8, 2024, ahead of PDUFA date.
FDA approval triggers $30M milestone payment from Blackstone to Autolus.
Cash and equivalents totaled $657.1M at Sep 30, 2024, up from $239.6M at Dec 31, 2023.
Net loss of $82.1M for Q3 2024 vs $45.8M in Q3 2023; diluted EPS -$0.31.
Matthias Will M.D. appointed Chief Development Officer effective Sep 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.